![](https://d3ilqtpdwi981i.cloudfront.net/o70Hs8DraHEZ4RJ1xpGd5L3mF9I=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/87/e0/39/87e03940-3b60-4b26-9c40-ff1c4aac383f/thumbnail_7a377c90-4c60-462c-8a8b-cb183cfb9872.jpg)
Prepulse inhibition (PPI) of acoustic startle is an operational measure of sensorimotor gating, which is disrupted in schizophrenia. NMDA receptor (NMDAR) antagonist induced PPI disruption has become an important pharmacological model for schizophrenia; however, knowledge of the underlying mechanism remains incomplete. This study examines the role of NMDAR in the caudal pontine reticular nucleus (PnC) and the medial prefrontal cortex (mPFC) in NMDARs antagonist induced PPI deficits, as well as the NMDA receptor subtypes involved. We administered the NMDA antagonist MK-801 locally into the caudal pontine reticular formation (PnC), where the PPI mediating pathway converges with the primary startle pathway, and into the mPFC prior to behavioural testing. PnC microinjections had no effect on startle and PPI, whereas injections into the ventro-rostral part, but not into the dorso-caudal part of the mPFC, disrupted PPI. These effects could be mimicked by local injection of the NR2B subunit specific antagonist ifenprodil, whereas co-application of MK-801 and the mGluR2/3 agonist LY354740 had no effect on PPI. Moreover, PPI disruptions by systemically administered MK-801 could be reversed by local injections of LY354740 into the ventro-rostral mPFC, but not into the dorso-caudal mPFC. Our results indicate that NR2B subunit containing NMDARs in a specific subregion of the mPFC play a major role in PPI disruptions by systemic NMDAR antagonism. Our results further support the hypothesis that glutamate hyper-function in the mPFC is a main mechanism involved in sensory gating deficits induced by systemic MK-801, supporting the notion that this is an important mechanism in schizophrenia pathology.
Available at: http://works.bepress.com/susanne-schmid/14/
This article has been accepted for publication in The International Journal of Neuropsychopharmacology, published by Oxford University Press and openly available at: https://doi.org/10.1017/S1461145713001041